Reader Comments
Post a new comment on this article
Post Your Discussion Comment
Please follow our guidelines for comments and review our competing interests policy. Comments that do not conform to our guidelines will be promptly removed and the user account disabled. The following must be avoided:
- Remarks that could be interpreted as allegations of misconduct
- Unsupported assertions or statements
- Inflammatory or insulting language
Thank You!
Thank you for taking the time to flag this posting; we review flagged postings on a regular basis.
closeParallel discussion going on at BMJ.com
Posted by plosmedicine on 31 Mar 2009 at 00:23 GMT
Author: Erick Turner
Position: Assistant Professor
Institution: Oregon Health & Science University
E-mail: turner@ohsu.edu
Submitted Date: March 14, 2008
Published Date: March 17, 2008
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.
For readers who are not aware of this, I would like to point out that the article by Kirsch, et. al. has also been the subject of some discussion in the BMJ.
At
http://www.bmj.com/cgi/co...
you will find an editorial by Robert Rosenthal, PhD and me regarding this article and a number of rapid responses to the editorial.
In addition, from 1998 to 2001, I served as a medical reviewer at the US Food and Drug Administration (FDA). Subsequently, but ending in 2005, I provided outside consulting to Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline. From 2004 to 2005, I was on the speaker's bureaus of Eli Lilly, AstraZeneca, and Bristol-Myers Squibb.